Compare Expeditors International of Wshngtn Inc (EXPD) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs Pfizer Inc — how do they compare? Expeditors International of Wshngtn Inc trades at $193.34 (market cap $25.18B), while Pfizer Inc trades at $27.99 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 6.3× Expeditors International of Wshngtn Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Expeditors International of Wshngtn Inc for 43 Days and Pfizer Inc for 158 Days on average.
| EXPD | PFE | |
|---|---|---|
Market Cap | $25.18B | $158.56B |
Volume | 1,003,557 | 44,138,282 |
Sector | Industrials | Health |
52-Week High | $194.12 | $29.02 |
52-Week Low | $113.13 | $23.67 |
Typical Hold Time | 43 Days | 158 Days |
Enterprise Value | $24.72B | $210.06B |
Dividend Yield | 0.84% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXPD trades at $190.85, down 0.5% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 expected at $2.20 EPS. Revenue growth is steady, rising from $10.6B in 2024 to a projected $12.0B in 2026, while net income margins remain stable around 7.6%. Recent news highlights efficiency initiatives and airfreight demand as positive catalysts.
Outlook is mixed: strong profitability and earnings beats support upside, but a high P/E of 28.2 suggests premium valuation risks. Analyst consensus is cautious with 63.6% hold ratings, and the consensus price target of $179.43 implies potential downside. Key risks include freight market volatility and execution challenges amid economic uncertainty.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
